Enhanced inhibition of neointimal hyperplasia by genetically engineered endothelial progenitor cells

Circulation. 2004 Apr 13;109(14):1769-75. doi: 10.1161/01.CIR.0000121732.85572.6F. Epub 2004 Apr 5.

Abstract

Background: Circulating endothelial progenitor cells (EPCs) have been reported previously. In this study, we examined the hypothesis that overexpression of vasculoprotective gene endothelial nitric oxide synthase (eNOS) and heme oxygenase-1 (HO-1) in EPCs enhances their ability to inhibit neointimal hyperplasia.

Methods and results: EPCs were isolated from rabbit peripheral blood, expanded in culture, and transduced with pseudotyped retroviral vectors expressing human eNOS (eNOS-EPCs), HO-1 (HO-1-EPCs), or green fluorescent protein (GFP-EPCs). Transduction efficiency of EPCs ex vivo was >90%. Four groups of rabbits (n=5 to 6 per group) were subjected to balloon angioplasty of the common carotid artery. Immediately after injury, approximately 5x10(6) autologous eNOS-EPCs or HO-1-EPCs were transplanted into the injured vessel. Control animals received an equivalent number of GFP-EPCs or Ringer's saline. Two weeks after transplantation, eNOS and HO-1 transgene transcripts and proteins were detected in the transduced rabbit vessels. Endothelialization was enhanced in the EPC-transplanted vessels independently of gene transfer. Neointimal thickening was significantly reduced in the GFP-EPC-treated vessels relative to the saline control. Neointima size was further reduced in vessels treated with eNOS-EPCs. Surprisingly, no additional reduction was seen in vessels treated with HO-1-EPCs relative to GFP-EPCs. Thrombosis occurred in approximately 50% of the saline-treated vessels but was virtually absent in all EPC-transplanted vessels.

Conclusions: We conclude that transplantation of autologous EPCs overexpressing eNOS in injured vessels enhances the vasculoprotective properties of the reconstituted endothelium, leading to inhibition of neointimal hyperplasia. This cell-based gene therapy strategy may be useful in treatment of vascular disease.

Publication types

  • Evaluation Study
  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Angioplasty, Balloon
  • Animals
  • Carotid Artery Injuries / pathology
  • Carotid Artery Injuries / surgery
  • Carotid Artery Injuries / therapy*
  • Carotid Artery, Common / pathology
  • Cells, Cultured / enzymology
  • Cells, Cultured / transplantation
  • DNA, Complementary / genetics
  • Endothelial Cells / enzymology
  • Endothelial Cells / transplantation*
  • Endothelium, Vascular / cytology
  • Enzyme Induction
  • Genes, Reporter
  • Genetic Therapy*
  • Genetic Vectors / genetics
  • Green Fluorescent Proteins
  • Heme Oxygenase (Decyclizing) / biosynthesis
  • Heme Oxygenase (Decyclizing) / genetics
  • Heme Oxygenase (Decyclizing) / physiology*
  • Heme Oxygenase-1
  • Humans
  • Hyperplasia
  • Luminescent Proteins / biosynthesis
  • Luminescent Proteins / genetics
  • Male
  • Membrane Proteins
  • Nitric Oxide Synthase / biosynthesis
  • Nitric Oxide Synthase / genetics
  • Nitric Oxide Synthase / physiology*
  • Nitric Oxide Synthase Type III
  • RNA, Messenger / biosynthesis
  • Rabbits
  • Recombinant Fusion Proteins / physiology
  • Retroviridae / genetics
  • Thrombosis / etiology
  • Thrombosis / prevention & control
  • Transduction, Genetic
  • Tunica Intima / pathology*

Substances

  • DNA, Complementary
  • Luminescent Proteins
  • Membrane Proteins
  • RNA, Messenger
  • Recombinant Fusion Proteins
  • Green Fluorescent Proteins
  • NOS3 protein, human
  • Nitric Oxide Synthase
  • Nitric Oxide Synthase Type III
  • HMOX1 protein, human
  • Heme Oxygenase (Decyclizing)
  • Heme Oxygenase-1